Proceedings of the 6th International Conference on Bioinformatics, Biotechnology, and Biomedical Engineering (BIOMIC 2025)

6th International Conference on Bioinformatics, Biotechnology, and Biomedical Engineering (BIOMIC 2025)

📍Yogyakarta, Indonesia🗓️ 30-31 July 2025
<Previous Article In Volume

Drug-Repurposing of Varespladib: Coagulation Activity Analysis Using In-Silico Pharmacokinetic, Pharmacological Network, and Molecular Docking Analysis

Authors
Alda Zaenida Nurul Raizma1, Muhammad Ode Rahmadhani1, Fajar Sofyantoro1, *
1Department of Tropical Biology, Faculty of Biology, Universitas Gadjah Mada, Yogyakarta, Indonesia
*Corresponding author. Email: fajar.sofyantoro@ugm.ac.id
Corresponding Author
Fajar Sofyantoro
Available Online 4 September 2026.
DOI
10.2991/978-94-6239-762-0_33How to use a DOI?
Keywords
Drug Repurposing; Hemorrhage; Network Pharmacology; Molecular Docking; Varespladib
Abstract

Pathological bleeding presents a significant clinical challenge due to limited effective anti-hemorrhagic therapies. Varespladib, originally developed as an anti-inflammatory agent has shown potential as a repurposed anti-hemorrhagic drug. Our study aimed to explore varespladib’s coagulation-modulating potential using in silico pharmacokinetics, pharmacological network, and molecular docking analysis. ADME profiles were evaluated via SwissADME, and target prediction was conducted using SwissTargetPrediction, GeneCards, and OMIM databases. Overlapping targets between varespladib and hemorrhage-associated genes were identified and analyzed using STRING and Cytoscape, with core proteins prioritized via the MCC (Maximal Clique Centrality) algorithm. Enrichment analyses using KEGG and Reactome confirmed strong associations between varespladib with coagulation-related pathways. Biological activity predictions via PASS indicated high phospholipase A2 inhibitory potential (Pa>0.9), while molecular docking showed strong binding affinities to key coagulation proteins, particularly FGA (Fibrinogen Alpha Chain) (–8.2 kcal·mol-1) and F2 (Coagulation Factor II) (–8.1 kcal·mol-1). Overall, the results support the potential of varespladib as a repurposed therapeutic candidate for hemorrhagic conditions, with further in vivo studies and clinical trials needed to confirm its efficacy and safety.

Copyright
© 2026 The Author(s)
Open Access
Open Access This chapter is licensed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits any noncommercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if you modified the licensed material. You do not have permission under this license to share adapted material derived from this chapter or parts of it.

Download article (PDF)

<Previous Article In Volume
Volume Title
Proceedings of the 6th International Conference on Bioinformatics, Biotechnology, and Biomedical Engineering (BIOMIC 2025)
Series
Advances in Health Sciences Research
Publication Date
4 September 2026
ISBN
978-94-6239-762-0
ISSN
2468-5739
DOI
10.2991/978-94-6239-762-0_33How to use a DOI?
Copyright
© 2026 The Author(s)
Open Access
Open Access This chapter is licensed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits any noncommercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if you modified the licensed material. You do not have permission under this license to share adapted material derived from this chapter or parts of it.

Cite this article

risenwbib
TY  - CONF
AU  - Alda Zaenida Nurul Raizma
AU  - Muhammad Ode Rahmadhani
AU  - Fajar Sofyantoro
PY  - 2026
DA  - 2026/09/04
TI  - Drug-Repurposing of Varespladib: Coagulation Activity Analysis Using In-Silico Pharmacokinetic, Pharmacological Network, and Molecular Docking Analysis
BT  - Proceedings of the 6th International Conference on Bioinformatics, Biotechnology, and Biomedical Engineering (BIOMIC 2025)
PB  - Atlantis Press
SP  - 533
EP  - 555
SN  - 2468-5739
UR  - https://doi.org/10.2991/978-94-6239-762-0_33
DO  - 10.2991/978-94-6239-762-0_33
ID  - Raizma2026
ER  -